Device Trial Radar · NCT05281237
Avecure Flexible Microwave Ablation Probe For Lung Nodules
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 1, 2022
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Beth Israel Deaconess Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MedWaves, Inc; Dana-Farber Cancer Institute
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)
Conditions
- Stage I - II Primary Lung Cancer
- Stage I Lung Cancer
- Stage II Lung Cancer
- Lung Cancer Stage I
- Lung Cancer Stage II
- Lung Cancer
Interventions
AveCure 16 Gauge Flexible Microwave Ablation ProbeDevice
Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Planned Ablations.Time frame: Day 1
- Pathological changes in the tumor tissue.Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.